ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update

ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update Lyon (France) and Cambridge, MA (U.S.), September 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second quarter 2021 conference call and webcast on Tuesday, September 21, 2021, at 2:30 PM CEST/8:30 AM ET to discuss operational highlights. The audio call is accessible via the below registering link: http://www.directeventreg.com/registration/event/6866536 (Conference ID : 6866536)Once registered, participants will receive a unique access code and the call number details to join the teleconference. The webcast can be followed live online via the link: https://edge.media-server.com/mmc/p/z2wjhmw4. An archived replay of the call will be available for 7 days by dialing + 1 855 859 2056, Conference ID: 6866536#. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com About ERYTECH ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out final results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing. ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.        For more information, please visit www.erytech.com         CONTACTS   ERYTECH                      Eric SoyerCFO & COOLifeSci Advisors, LLCCorey Davis, Ph.D.Investor RelationsNewCapMathilde Bohin / Louis-Victor DelouvrierInvestor relationsNicolas MerigeauMedia relations+33 4 78 74 44 [email protected]+1 (212) 915 – 2577 [email protected]+33 1 44 71 94 94 [email protected]
Attachment

ERYTECH_PR_2021_H1_Ccall-announcement_EN